

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The results from a Phase III study evaluating a liposomal encapsulation of cytarabine and daunorubicin (CPX-351) versus the conventional cytarabine/daunorubicin chemotherapy (7+3 regimen) have shown a significantly prolonged overall survival with CPX-351 for patients aged 60 to 75 years with _____.
 - Primary acute myeloid leukemia (AML)
 - Secondary AML
 - NPM1-mutated AML
 - Both a and b
 - All of the above
- Ivosidenib is FDA approved for adult patients with relapsed or refractory AML with which of the following mutations?
 - FLT3
 - NPM1
 - IDH1
 - IDH2
- In a Phase I study of venetoclax in combination with a hypomethylating agent for elderly patients with previously untreated AML, the combination of venetoclax and azacitidine demonstrated a _____ remission rate and a tolerable safety profile.
 - Low (about 20%)
 - High (higher than 60%)
- _____ is an investigational tyrosine kinase inhibitor that targets both the FLT3-ITD (internal tandem duplication) mutations and the FLT3-TKD (tyrosine kinase domain) point mutations in patients with FLT3 mutation-positive AML.
 - Quizartinib
 - Gilteritinib
 - Both a and b
 - None of the above
- Treatment of AML with the multitargeted tyrosine kinase inhibitor sorafenib results in _____.
 - Anti-angiogenesis
 - Increased IL-15 levels
 - FLT3 inhibition
 - All of the above
- The preemptive measurement of minimal residual disease (MRD) in patients with AML can _____.
 - Guide clinicians regarding treatment with azacitidine
 - Assist clinicians in the assessment of prognosis
 - Both a and b
 - Neither a nor b
- Tisagenlecleucel, a CD19-directed genetically modified autologous T-cell immunotherapy, is FDA approved for the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) in children and young adults.
 - True
 - False
- Blinatumomab is currently FDA approved for adults and children in which of the following populations of patients with ALL?
 - MRD-positive
 - Relapsed/refractory B-cell precursor
 - Treatment-naïve B-cell precursor
 - Both a and b
 - Both b and c
 - All of the above
- Inotuzumab ozogamicin is a _____ that is FDA approved for the treatment of relapsed/refractory ALL.
 - Chimeric antigen receptor T-cell therapy
 - Bispecific T-cell engager antibody
 - CD22-directed antibody-drug conjugate
 - None of the above

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

10. Treatment of newly diagnosed acute promyelocytic leukemia (APL) with the combination of all-trans retinoic acid and arsenic trioxide resulted in favorable long-term outcomes for patients with non-high-risk disease (white blood cell counts lower than $10 \times 10^9/L$ at diagnosis) and patients with high-risk disease (white blood cell counts higher than $10 \times 10^9/L$ at diagnosis) who previously received gemtuzumab ozogamicin.

a. True

b. False